Literature DB >> 32039264

Survival analysis of multiple myeloma patients after autologous stem cell transplantation.

Ju Li1, Yan Zhu1.   

Abstract

BACKGROUND: Hematopoietic stem cell transplantation has been applied to treat the hematologic malignancies since the 1980s. However, allogenic transplantation has inherent complications such as graft-versus-host disease and graft failure. Autologous transplantation has become more and more popular because of its lower transplant-related mortality. This study was performed to analyze the possible prognostic factors for myeloma patients post stem cell transplantation.
METHODS: Patients' information was collected by history review and follow-up through the phone call. Kaplan-Meier was used to exhibit overall survival (OS) and progression-free survival (PFS). Univariate and multivariate analyses were performed using Cox proportional hazards model. A P<0.05 is considered statistically significant.
RESULTS: Thirty patients with multiple myeloma were included in this study, 7 of them died because of myeloma relapse and myeloma-associated complications. The average survival time was 29.8 months and the median follow-up was 25.1 months. The 1-year OS and PFS were 93.3% and 90.0%, respectively. Both the 3-year OS and PFS were 76.7%. In a variety of factors, improved renal function showed a good effect on the outcome of transplantation.
CONCLUSIONS: To prevent cancer relapse after autologous transplantation, it is of great significance to achieve a complete remission prior to the transplantation. 2019 Stem Cell Investigation. All rights reserved.

Entities:  

Keywords:  Multiple myeloma; hematopoietic stem cell transplantation (HSCT); retrospective study; survival analysis

Year:  2019        PMID: 32039264      PMCID: PMC6987323          DOI: 10.21037/sci.2019.10.05

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  37 in total

1.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Shaji K Kumar; Natalie S Callander; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Matthew Faiman; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Michaela Liedtke; Thomas Martin; James Omel; Noopur Raje; Frederic J Reu; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2017-02       Impact factor: 11.908

Review 2.  Multiple myeloma.

Authors:  Gautam Raju Mehta; Faten Suhail; Rami Y Haddad; Ghassan Zalzaleh; Edgar V Lerma
Journal:  Dis Mon       Date:  2014-10-03       Impact factor: 3.800

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

Review 4.  Do negative or positive emotions differentially impact mortality after adult stem cell transplant?

Authors:  F Hoodin; J P Uberti; T J Lynch; P Steele; V Ratanatharathorn
Journal:  Bone Marrow Transplant       Date:  2006-06-19       Impact factor: 5.483

5.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

6.  [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].

Authors:  K Okada; N Oguchi; K Shinohara; N Tamura; K Ishii; Y Noguchi; S Hayashi; H Yamamoto; M Takeichi; H Fujimoto; T Shirota; T Hayashi
Journal:  Rinsho Ketsueki       Date:  1997-12

7.  Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.

Authors:  Julie M Vose; Douglas J Rizzo; Jing Tao-Wu; James O Armitage; Asad Bashey; Linda J Burns; Neal Paul Christiansen; Cesar O Freytes; Robert Peter Gale; John Gibson; Sergio A Giralt; Roger H Herzig; Charles F Lemaistre; Philip L McCarthy; Stephen D Nimer; Finn B Petersen; David P Schenkein; Peter H Wiernik; Joseph M Wiley; Fausto R Loberiza; Hillard M Lazarus; Koen van Biesen; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2004-02       Impact factor: 5.742

8.  Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

Authors:  Natacha Heutte; Henning H Flechtner; Nicolas Mounier; Wilhelmina A M Mellink; Jacobus H Meerwaldt; Houchingue Eghbali; Mars B van't Veer; Evert M Noordijk; Johanna C Kluin-Nelemans; Elzbieta Lampka; José Thomas; Pieternella J Lugtenburg; Luisa Viterbo; Patrice Carde; Anton Hagenbeek; Richard Wm van der Maazen; Wilma G J M Smit; Pauline Brice; Marinus van Marwijk Kooy; Johanna W Baars; Philip Poortmans; Umberto Tirelli; Onno C Leeksma; Radka Tomsic; Pierre Feugier; Gilles Salles; Jean Gabarre; Marie José Kersten; Eric Van Den Neste; Geert-Jan M Creemers; Isabelle Gaillard; Paul Meijnders; Gérard Tertian; Oumédaly Reman; Hein P Muller; Jacques Troncy; Michel Blanc; Wilfried Schroyens; Paul J Voogt; Pierre Wijermans; Chantal Rieux; Christophe Fermé; Michel Henry-Amar
Journal:  Lancet Oncol       Date:  2009-10-12       Impact factor: 41.316

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

10.  Peri-transplant psychosocial factors and neutrophil recovery following hematopoietic stem cell transplantation.

Authors:  Jennifer M Knight; Jan A Moynihan; Jeffrey M Lyness; Yinglin Xia; Xin Tu; Susan Messing; Bryan C Hunter; Li-Shan Huang; Rosemary O Obi; D'Arcy Gaisser; Jane L Liesveld; Olle Jane Z Sahler
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

View more
  1 in total

Review 1.  Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma.

Authors:  Ikhwan Rinaldi; Abdul Muthalib; Brenda Cristie Edina; Lowilius Wiyono; Kevin Winston
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.